ArticleVaccines2022
Prioritization of Vaccines for Inclusion into China's Expanded Program on Immunization: Evidence from Experts' Knowledge and Opinions.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Factors influencing healthcare workers' vaccine recommendations: A cross-sectional study in Zhejiang Province, China.Human vaccines & immunotherapeutics · 2025Article
- A discrete choice experiment on Chinese parents' preferences of vaccine schedules against six childhood infectious diseases.Vaccine: X · 2025Article
- Public Preference and Priorities for Including Vaccines in China's National Immunization Program: Discrete Choice Experiment.JMIR public health and surveillance · 2024Article
- The equity road ahead for financing non-national immunization program vaccines in China: challenges and opportunities from a qualitative study.International journal for equity in health · 2024Article
- Review
- The coverage and challenges of increasing uptake of non-National Immunization Program vaccines in China: a scoping review.Infectious diseases of poverty · 2023Article
- Adding new childhood vaccines to China's National Immunization Program: evidence, benefits, and priorities.The Lancet. Public health · 2023Review
- An Autoregressive Integrated Moving Average Model for Predicting Varicella Outbreaks - China, 2019.China CDC weekly · 2023Article
- Vaccine pricing strategies in China.BMJ global health · 2023Article
- Spatiotemporal and Seasonal Trends of Class A and B Notifiable Infectious Diseases in China: Retrospective Analysis.JMIR public health and surveillance · 2023Article
- First Year of Special Issue "New Insights in Vaccination and Public Health": Opinions and Considerations.Vaccines · 2023Article
- Epidemiological Characteristics of Varicella under Different Immunisation Strategies in Suzhou Prefecture, Jiangsu Province.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundVaccine developers in China have made an increasing number of infectious diseases preventable through vaccination. An appropriate decision-making procedure is necessary for making wise decisions on whether to introduce new vaccines into the Expanded Program on Immunization (EPI). When there are several vaccines that could potentially be considered, a scientifically justifiable mechanism is needed for prioritizing and sequencing vaccines for consideration.
methodsWe used a modified Delphi technique (MDT) to develop and refine an indicator system to prioritize vaccines and make policy recommendations concerning their introduction into China's EPI system. From January through May 2021, thirty-nine experts were recruited and participated in a two-round Delphi survey that was based on a set of candidate indicators obtained through a literature review and reference to the WHO vaccine introduction recommendations. Using the resulting indicator system, we conducted a third consultation with a multi-disciplinary group of experts who scored five program-eligible candidate vaccines to determine prioritization and sequencing for consideration of inclusion into the EPI.
resultsResponse rates of the thirty-nine experts were 100% and 97.4% across the two rounds. Authority coefficients from rounds one to three were over 0.70, reflecting the high accuracy and reliability of the consultation. Coordination coefficients of importance scores for primary, secondary, and tertiary indicators were 0.486, 0.356, 0.275 in round one, and 0.405, 0.340, and 0.236 in round two. According to the scores from 30 experts using our indicator system, the sequence and scores (1-10 scale, 10 highest) of 5 candidate vaccines were varicella (6.91), meningococcal conjugate AC (6.83), Hib (6.74), influenza (6.56), and EV71 (6.17) vaccines.
conclusionsA modified Delphi technique effectively built a scientific, rational, comprehensive, and systematic indicator system for prioritizing vaccine candidates for consideration of inclusion into the EPI. The rank order will be used by the technical working groups of China's National Immunization Advisory Committee to sequentially develop and present Evidence-to-Recommendation tables for making policy recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.